X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AC-1101 (tofacitinib) topical gel phase I study patients with granuloma annulare. The oral formulation of tofacitinib has already been FDA approved to treat such ailments as rheumatoid arthritis.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Rare Diseases and Disorders Product Name: AC-1101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2023
Details:
Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.
Lead Product(s): CAS 139481-59-7
Therapeutic Area: Genetic Disease Product Name: AC-203
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Winhealth Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 06, 2021
Details:
Health Canada has approved Ancheng Biotech's open-label, fixed-sequence, two-period, comparative bioavailability study of AC-1101 (Tofacitinib Citrate). Tofacitinib Citrate is a topical JAK inhibitor for the treatment of vitiligo.
Lead Product(s): Tofacitinib Citrate
Therapeutic Area: Dermatology Product Name: AC-1101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
